\n\u00a0\n<\/p>\n<\/td>\n
Q1 2025<\/b><\/p>\n<\/td>\n
% Change<\/b><\/p>\n<\/td>\n
\n\u00a0\n<\/p>\n<\/td>\n
\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n
\n\u00a0\n<\/p>\n<\/td>\n
$m<\/b><\/p>\n<\/td>\n
Actual<\/b><\/p>\n<\/td>\n
CER<\/b>1<\/sup><\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n – Product Sales<\/i><\/p>\n<\/td>\n \n12,875\n<\/p>\n<\/td>\n \n6\n<\/p>\n<\/td>\n \n9\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n – Alliance Revenue<\/i><\/p>\n<\/td>\n \n639\n<\/p>\n<\/td>\n \n40\n<\/p>\n<\/td>\n \n42\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \nProduct Revenue2<\/sup><\/p>\n<\/td>\n \n13,514\n<\/p>\n<\/td>\n \n7\n<\/p>\n<\/td>\n \n10\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n \nCollaboration Revenue\n<\/p>\n<\/td>\n \n74\n<\/p>\n<\/td>\n \n64\n<\/p>\n<\/td>\n \n64\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n Total Revenue<\/b><\/p>\n<\/td>\n 13,588<\/b><\/p>\n<\/td>\n 7<\/b><\/p>\n<\/td>\n 10<\/b><\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n Reported EPS ($)<\/b><\/p>\n<\/td>\n 1.88<\/b><\/p>\n<\/td>\n 34<\/b><\/p>\n<\/td>\n 32<\/b><\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n Core<\/b>3<\/sup>EPS($)<\/b><\/p>\n<\/td>\n 2.49<\/b><\/p>\n<\/td>\n 21<\/b><\/p>\n<\/td>\n 21<\/b><\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n \n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n Key performance elements for Q1 2025<\/span><\/p>\n \n(Growth numbers at constant exchange rates)\n<\/p>\n Pascal Soriot, Chief Executive Officer, AstraZeneca, said:<\/span><\/p>\n \n“Our strong growth momentum has continued into 2025 and we have now entered an unprecedented catalyst-rich period for our company.\n<\/p>\n \nAlready this year we have announced five positive Phase III study readouts, including most recently the highly anticipated DESTINY-Breast09 for Enhertu, as well as SERENA-6 for camizestrant and MATTERHORN for Imfinzi; the latter two of these will feature in the ASCO 2025 plenary sessions, reflecting the significance of these data to the oncology community.\n<\/p>\n \nOur company is firmly committed to investing and growing in the US and we continue to benefit from our broad-based source of revenue and global manufacturing footprint, including elevenproduction sites in the US covering small molecules, biologics as well as cell therapy. Additionally, we have even greater US investment in manufacturing and R&D planned, leveraging our two large R&D sites in Gaithersburg MD and Cambridge MA.\n<\/p>\n \nOverall, we are making excellent progress toward our ambition of eighty billion dollars in Total Revenue by 2030.”\n<\/p>\n \nSee Table 1 for details of clinical trial results since the prior earnings announcement, including DESTINY-Breast09, MATTERHORN, and SERENA-6.\n<\/p>\n \nSee Note 4 for the locations of the eleven US manufacturing sites.\n<\/p>\n Guidance<\/span><\/p>\n \nAstraZeneca reiterates its Total Revenue and Core EPS guidance5<\/sup> for FY 2025 at CER, based on the average foreign exchange rates through 2024.\n<\/p>\n Total Revenue<\/b> is expected to increase by a high single-digit<\/b> percentage\n<\/p>\n Core EPS<\/b> is expected to increase by a low double-digit<\/b> percentage\n<\/p>\n \n\u2013 The Core Tax rate is expected to be between 18-22%\n<\/p>\n \n\u2013 If foreign exchange rates for April 2025 to December 2025 were to remain at the average rates seen in March 2025, it is anticipated that compared to the performance at CER, FY 2025 Total Revenue would incur a low single-digit percentage adverse impact (unchanged from prior guidance), and Core EPS would incur a low single-digit percentage adverse impact (previously mid single-digit).\n<\/p>\n \nResults highlights\n<\/p>\n \nTable 1. Milestones achieved since the prior results announcement\n<\/p>\n \nPhase III and other registrational data readouts\n<\/p>\n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20250428918895\/en\/2301168\/3\/original.jpg\")
<\/td>\n<\/tr>\n